This pharmacovigilance study identified two clinically significant signals: DRESS as a unique safety concern for caspofungin, and striking resistance signals for caspofungin and micafungin.
Abstract
Aim This pharmacovigilance study analyzed echinocandin-related adverse events (AEs) using the FDA Adverse Event Reporting System (FAERS) database to identify agent-specific safety signals and inform clinical decision-making. Methods AE reports were extracted from FAERS covering Q1 2004 to Q4 2025. Four disproportionality algorithms—reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC025), and empirical Bayesian geometric mean (EBGM05)—were applied. Positive signals were defined when all four methods yielded positive results. Results A total of 5,298 cases with echinocandins as the primary suspect drug were included. Caspofungin showed unique association with DRESS syndrome (ROR = 16.62, IC025 = 3.21). Exceptionally strong resistance signals were detected for caspofungin (“pathogen resistance”: ROR = 68.83; “drug resistance”: ROR = 22.32) and micafungin (“bronchopulmonary aspergillosis”: ROR = 71.99; “Candida infection”: ROR = 23.93). Hepatobiliary signals included cholestasis (ROR = 24.97) and alkaline phosphatase increase (ROR = 19.10) for caspofungin, with similar signals observed for micafungin and anidulafungin. Conclusion This pharmacovigilance study identified two clinically significant signals: DRESS as a unique safety concern for caspofungin, and striking resistance signals for caspofungin and micafungin. These findings emphasize the need for vigilant monitoring during echinocandin therapy and reinforce antifungal stewardship.
AAE is reported not as a single uniform event but with profiles specific to the causative antibiotic, which may support earlier recognition, although confirmation in analytic studies with exposure denominators is warranted.
Background Ifosfamide, an alkylating agent used to treat various malignancies, has limited real-world safety data on neurotoxicity. Therefore, this study analyzed ifosfamide-related Central Nervous System Adverse Events (CNS AEs) to provide a reference for drug risk management. Methods The disproportionality study was...
Pei-Qi Shi, Qing-Hua Mei, Rong-Jie Zheng et al.· Frontiers in Oncology· 0 citations
ABSTRACT Tocilizumab, a humanized monoclonal antibody targeting the interleukin-6 receptor, is widely used in immune-mediated diseases, yet its real-world safety in pediatric populations remains insufficiently characterized. This retrospective pharmacovigilance study analyzed adverse event (AE) reports from the U.S. Fo...
Gang Wu, Xue-Qing Ma, Bin Zhu et al.· Human Vaccines & Immunothera...· 1 citation
Voriconazole (VCZ) has a narrow therapeutic window and is metabolized by CYP450 enzymes, predisposing it to adverse drug events (ADEs) and drug-drug interactions (DDIs), yet its multisystem safety profile and combination-therapy characteristics in real‑world practice remain inadequately understood. To address this gap,...
Yi-Yu Feng, Tao Zhao, Jia-Min Zhu et al.· International Journal of Cli...· 0 citations
Abstract This study conducted a retrospective disproportionality analysis of 50,031 adverse drug event (ADE) reports from the FDA Adverse Event Reporting System (FAERS) database spanning Q2 2009 to Q3 2025, in which golimumab was identified as the primary suspect drug. Four disproportionality algorithms were simultaneo...
This large-scale spontaneous-reporting study detected potential safety signals in children using FAERS data from 2017 to 2025, and indicated distinct patterns of adverse‑event reporting across age and sex strata.
Xue-Qing Ma, Jiao-Jiao Fan, Ben Liu· Human Vaccines & Immunothera...· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.